Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia

Guler, Tumer Erdem; DOĞDUŞ, Mustafa

Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia

Mustafa Doğduş, (Karaman Devlet Hastanesi, Kardiyoloji Bölümü, Karaman, Türkiye)

Tümer Erdem GÜLER (Kocaeli Derince Eğitim ve Araştırma Hastanesi, Kardiyoloji Bölümü, Kocaeli, Türkiye)

Kocaeli Tıp Dergisi

1 1

Yıl: 2019 Cilt: 8 Sayı: 2 Sayfa Aralığı: 173 - 181 Metin Dili: İngilizce İndeks Tarihi: 04-06-2020

Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia

Öz:

ABSTRACTINTRODUCTION: The pathophysiology of coronary artery ectasia (CAE) has not been clearly identified. Dyslipidemia is considered an independent risk factor for cardiovascular disease (CVD). Although the relationship between atherogenicdyslipidemia and CVD is well known, there is no information about atherogenic dyslipidemia with isolated CAE. The aim of the present study was to evaluate the atherogenic dyslipidemia in patients with isolated CAE.METHODS: The patient group included 91 patients with isolated CAE and the control group consisted of 90 consecutive subjects who proved to have normal coronary angiograms. Serum levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), andatherogenic indices (atherogenic dyslipidemia index, non HDL-C, atherogenic coefficient, cardiac risk ratios 1 and 2) were analyzed.RESULTS: The atherogenic dyslipidemia index, non HDL-C, atherogenic coefficient, and cardiac risk ratios 1 and 2 were significantly greater in the isolated CAE patients than in the controls (p < 0.001; p = 0.001; p = 0.001; p = 0.001; p < 0.001, respectively). The multivariate logistic regression models revealed that atherogenic dyslipidemia index was found to be independent factor predicting isolated CAE (p < 0.001, Odds ratio (OR) = 1.329, 95% Confidence interval (C.I.) = 1.110–1.591).DISCUSSION and CONCLUSION: This is the first study that evaluates the relationship between the atherogenic dyslipidemia and isolated CAE. Our findings suggest that increased atherogenic indices (atherogenic dyslipidemia index, non HDL-C, atherogenic coefficient, cardiac risk ratios 1 and 2) may be involved in the early pathogenesis of the isolated CAE.

Anahtar Kelime:

İzole Kroner Arter Ektazili Hastalarda Aterojenik Dislipideminin Araştırılması

Öz:

ÖZGİRİŞ ve AMAÇ: Koroner arter ektazisinin (KAE) patofizyolojisi açıkça tanımlanamamıştır. Dislipidemi, kardiyovasküler hastalık (KVH) için bağımsız bir risk faktörü olarak kabul edilir. Her ne kadar aterojenik dislipidemi ile KVH arasındaki ilişki iyi bilinse de, izole KAE ile aterojenik dislipidemi hakkında bilgi yoktur. Bu çalışmanın amacı, izole KAE'li hastalarda aterojenik dislipidemiyi değerlendirmektir.YÖNTEM ve GEREÇLER: Hasta grubunda izole KAE olan 91 hasta vardı ve kontrol grubu normal koroner anjiyogramları olan 90 ardışık kişiden oluşuyordu. Serum total kolesterol (TK), trigliserit (TG), düşük yoğunluklu lipoprotein kolesterol (LDL-K), yüksek yoğunluklu lipoprotein kolesterol (HDL-K) ve aterojenik endeksler (aterojenik dislipidemi indeksi, HDL-K olmayan, aterojenik katsayısı, kardiyak risk oranları 1 ve 2) analiz edildi.BULGULAR: Aterojenik dislipidemi indeksi, HDL-K olmayan, aterojenik katsayısı ve kardiyak risk oranları 1 ve 2 izole KAE hastalarında kontrollerden anlamlı olarak daha yüksekti (p <0.001; p = 0.001; p = 0.001; p = 0.001; p <0,001, sırasıyla). Çok değişkenli lojistik regresyon modelleri, aterojenik dislipidemi endeksinin izole KAE'yi öngören bağımsız faktör olduğunu ortaya koymuştur (p <0.001, Odds oranı (OR) = 1.329,% 95 Güven aralığı (C.I.) = 1.110-1.591).TARTIŞMA ve SONUÇ: Bu çalışma, aterojenik dislipidemi ile izole KAE arasındaki ilişkiyi değerlendiren ilk çalışmadır. Bulgularımız, artmış aterojenik endekslerin (aterojenik dislipidemi indeksi, HDL-K olmayan, aterojenik katsayısı, kardiyak risk oranları 1 ve 2) izole KAE'nin erken dönem patogenezinde rol oynayabileceğini göstermektedir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Swaye P, Fisher L, Litwin P, et al. Aneurysmal coronary artery disease. Circulation 1983; 67: 134-8.
2. Sorrell V, Davis M, Bove A. Current knowledge and significance of coronary artery ectasia: a chronologic review of the literature, recommendations for treatment, possible etiologies, and future considerations. Clin Cardiol 1998; 21:157-60.
3. Sultana R, Sultana N, Ishaq M, et al. The prevalence and clinical profile of angiographic coronary ectasia. J Pak Med Assoc. 2011; 61(4): 372–5.
4. Aksu T, Uygur B, Kosar M, et al. Coronary artery ectasia: its frequency and relationship with atherosclerotic risk factors in patients undergoing cardiac catheterization. Anadolu Kardiyol Derg. 2011;11(4):280–4.
5. Pinar Bermúdez E, López Palop R, Lozano Martínez-Luengas I, et al. Coronary ectasia: prevalence, and clinical and angiographic characteristics. Revista Espan˜ola de Cardiologia. 2003;56(5):473–9.
6. Harikrishnan S, Krishnakumar N, Jaganmohan T. Coronary artery ectasia–is it time for reappraisal? Clin Cardiol. 2007;30(10):536.
7. Kaya MG. Inflammation and coronary artery disease: as a new biomarker neutrophil/lymphocyte ratio. Turk Kardiyol Dern Ars 2013; 41: 191–2.
8. Yilmaz M, Korkmaz H, Bilen MN, Uku O, Kurtoglu E. Could neutrophil/lymphocyte ratio be an indicator of coronary artery disease, coronary artery ectasia and coronary slow flow? J Int Med Res. 2016 Dec;44(6):1443-53.
9. Hartnell GG, Parnell BM, Pridie RB. Coronary artery ectasia. Its prevalence and clinical significance in 4,993 patients. Br Heart J. 1985;54(4):392–5.
10. Nwagha UI, Ikekpeazu EJ, Ejezie FE, Neboh EE, Maduka IC. Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. African Health Sciences Sep 2010; 10(3): 248–52.
11. Igweh JC, Nwagha IU, Okaro JM. The Effects of Menopause on the Serum lipid profile of Normal Females of South East Nigeria. Nigerian Journal of Physiological Sciences 2005; 20(1 2): 48- 53.
12. Mudhaffar SK. Atherogenic Index of Plasma (AIP) As a Parameter in Predicting Cardiovascular Risk in Males Compared To the Conventional Dyslipidemic Indices (Cholesterol Ratios). Karbala J. Med. 2013 June; 6(1):1506-13.
13. Guerin M, Legoff W, Lassel TS, VanTol A, Steiner G, Chapman MJ. Proatherogenic role of elevated CE transfer from HDL to VLDL and dense LDL in type 2 diabetics. Arterioscler Thromb Vasc Biol 2001; 21:282-87.
14. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo B- lipoprotein-depleted plasma. (FERHDL). Clin Biochem 2001; 34:583- 88.
15. Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem 2004; 50:1184-88. 16. Nwagha UI, Igweh JC. Atherogenic Index of Plasma: A significant indicator for the onset of Atherosclerosis during menopause in hypertensive females of South East Nigeria. Journal of College of Medicine 2005;10(2):67-71.
17. Njajou O, Kanaya AM, Holvoet P, Connelly S, Harris T. Association between oxidized LDL-C, obesity and type 2 diabetes. Diabetes Metab. Res. rev 2009;25(8):733-9.
18. Daniels LB, Laughlin G, Sarno MJ. LpPLA2 is an independent predictor of incident coronary heart disease in apparently healthy older population. J. Am. Col. Cadiol 2008;51:913-9.
19. Tariq M, Ali Rajab. Comparative study for Atherogenic Index of Plasma (AIP) in patient with type1 Diabetes Mellitus, type2 Diabetes Mellitus, Betathalassemia and Hypothyroidism. Int. J. Chem. Res 2012;2(1-9).
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of LDL-C in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
21. Ikewuchi JC, Ikewuchi JC. Alteration of plasma lipid profiles and atherogenic indeces by Stachytarpheta iamaicensis L. (Vahl). Biokemistri. 2009; 21(2): 71-7.
22. Ahmadvand H, Ghasemi-Dehnoo M. Antiatherogenic, hepatoprotective, and hypolipidemic effects of coenzyme Q10 in alloxaninduced type 1 diabetic rats. ARYA Atheroscler. 2014 Jul;10(4):192-8.
23. Ahmadvand H, Noori A, Ghasemi Dehnoo M, Bagheri S, Cheraghi RA. Hypoglycemic, hypolipidemic and antiatherogenic effects of oleuropein in alloxan-induced Type 1 diabetic rats. Asian Pac J Trop Dis. 2014; 4(Suppl 1):S421-S425
24. Falsetti HL, Carroll RJ: Coronary artery aneurysm. A review of the literature with a report of 11 new cases. Chest, 1976; 69: 630–36.
25. Markis JE, Joffe CD, Cohen PF, et al. Clinical significance of coronary arterial ectasia. Am J Cardiol. 1976; 37:217–22.
26. Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014; 348(2):108-14.
27. Baliarsingh S, Sharma N, Mukherjee R. Serum uric acid: marker for atherosclerosis as it is positively associated with "atherogenic index of plasma". Arch Physiol Biochem. 2013;119(1): 27- 31.
28. Cheraghi M, Shahsavari G, Maleki A, Ahmadvand H. Paraoxonase 1 Activity, Lipid Profile, and Atherogenic Indexes Status in Coronary Heart Disease. Rep Biochem Mol Biol. 2017 Oct;6(1):1-7.
29. Demopoulos V, Olympios C, Fakiolas C, et al. The natural history of aneurysmal coronary artery disease. Heart 1997; 78: 136 141.
30. Swanton RH, Lea TM, Coltarte DJ, et al. Coronary artery ectasia, a variant of occlusive coronary arteriosclerosis. Br Heart J 1978; 40: 393– 400.
31. Sudhir K, Ports TA, Amidon TM, Goldberger JJ, Bhushan V, Kane JP, Yock P, Malloy MJ. Increased prevalence of coronary ectasia in heterozygous familial hypercholesterolemia. Circulation. 1995 Mar 1;91(5):1375-80.
32. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005; 96: 1576-8.
33. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract 2005; 59: 1276-82.
34. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1995; 141:637-44.
35. Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980; 68:401-4.
36. Sen N, Ozcan F, Uygur B, Aksu T, Akpinar I, Cay S, Cetin M, Sokmen E, Akcakoyun M, Maden O, Balbay Y, Erbay AR. Elevated serum uric acid levels in patients with isolated coronary artery ectasia. Turk Kardiyol Dern Ars. 2009 Oct;37(7):467-72.
37. Mathur A, Robinson MS, Cotton J, et al. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85: 989–994.
38. Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399–404.
39. Demir S, Avsar MK, Karakaya Z, Selcuk M, Tosu AN, Abal G, Tokuccu E, Demir M. Increased mean platelet volume is associated with coronary artery ectasia. Postepy Kardiol Interwencyjnej. 2013;9(3):241-5.
40. Bitigen A, Tanalp AC, Elonu OH, Karavelioglu Y, Ozdemir N. Mean platelet volume in patients with isolated coronary artery ectasia. J Thromb Thrombolysis. 2007 Oct;24(2):99-103.
41. Levinson SS. Relationship between bilirubin, apolipoprotein B,and coronary artery disease. Ann Clin Lab Sci 1997; 27: 185-92.
42. Demir M, Demir C, Uyan U, et al. The relationship between serum bilirubin concentration and atrial fibrillation. Cardiol Res 2013; 4: 186-91.
43. Demir M, Demir C, Keceoglu S. The relationship between serum bilirubin concentration and coronary artery ectasia. Postepy Kardiol Interwencyjnej.2015;11(3):202-5.

APA	DOĞDUŞ M, Guler T (2019). Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. , 173 - 181.
Chicago	DOĞDUŞ Mustafa,Guler Tumer Erdem Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. (2019): 173 - 181.
MLA	DOĞDUŞ Mustafa,Guler Tumer Erdem Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. , 2019, ss.173 - 181.
AMA	DOĞDUŞ M,Guler T Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. . 2019; 173 - 181.
Vancouver	DOĞDUŞ M,Guler T Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. . 2019; 173 - 181.
IEEE	DOĞDUŞ M,Guler T "Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia." , ss.173 - 181, 2019.
ISNAD	DOĞDUŞ, Mustafa - Guler, Tumer Erdem. "Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia". (2019), 173-181.

APA	DOĞDUŞ M, Guler T (2019). Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. Kocaeli Tıp Dergisi, 8(2), 173 - 181.
Chicago	DOĞDUŞ Mustafa,Guler Tumer Erdem Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. Kocaeli Tıp Dergisi 8, no.2 (2019): 173 - 181.
MLA	DOĞDUŞ Mustafa,Guler Tumer Erdem Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. Kocaeli Tıp Dergisi, vol.8, no.2, 2019, ss.173 - 181.
AMA	DOĞDUŞ M,Guler T Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. Kocaeli Tıp Dergisi. 2019; 8(2): 173 - 181.
Vancouver	DOĞDUŞ M,Guler T Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia. Kocaeli Tıp Dergisi. 2019; 8(2): 173 - 181.
IEEE	DOĞDUŞ M,Guler T "Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia." Kocaeli Tıp Dergisi, 8, ss.173 - 181, 2019.
ISNAD	DOĞDUŞ, Mustafa - Guler, Tumer Erdem. "Investigation of Atherogenic Dyslipidemia in Patients with İsolated Coronary Artery Ectasia". Kocaeli Tıp Dergisi 8/2 (2019), 173-181.